Browse by Person

Export as [feed] Atom [feed] RSS
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 5.


Eisen, T., Frangou, E., Oza, B. et al. (22 more authors) (2020) Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 38 (34). pp. 4064-4075. ISSN 0732-183X

Bullement, A., Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Ricketts, C.J., Morris, M.R., Gentle, D. et al. (7 more authors) (2013) Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics, 5. 16. ISSN 1868-7075

This list was generated on Sun Oct 17 08:25:37 2021 BST.